PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Bladder Cancer|HER2-positive Solid Tumor
Interventions: DRUG: PRS-343 in Combination with Atezolizumab
Sponsor: Pieris Pharmaceuticals, Inc.